Global Influenza A Infections Therapeutics Pipeline Review 2014 - Analysis of 23 Companies & 41 Drug profiles
M2 - Tue Apr 29, 8:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wjnvgk/influenza_a) has announced the addition of the "Influenza A Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Influenza A Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Influenza A Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Influenza A Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Influenza A Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Influenza A Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Influenza A Infections - Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Autoimmune Technologies, LLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Vertex Pharmaceuticals Incorporated - Crucell N.V. - Hemispherx Biopharma, Inc. - Amarillo Biosciences, Inc. - SIGA Technologies, Inc. - Vironova AB - CureVac GmbH - PT Bio Farma - Viroblock S.A. - Innate Therapeutics Limited - Chimerix, Inc. - Theraclone Sciences, Inc. - Immune Targeting Systems (ITS) Ltd. - Sinovac Biotech Ltd. - Microbiotix, Inc. - Alios BioPharma, Inc. - ImmuneRegen BioSciences, Inc. - Vivaldi Biosciences Inc. - Humabs BioMed SA Drug Profiles - diridavumab - interferon alfa - FP-01 - CR-8020 - TCN-032 - midodrine hydrochloride - VX-787 - Avian Flu Vaccine - RG-7745 - Influenza A H7N7 vaccine - VIS-410 - Orvax - GSK-3206641-A - GSK-3206640A - H7N9 Vaccine - Homspera - rintatolimod - interferon alfa-n3 (human leukocyte derived) - Drug For Influenza A Infections - MIS-416 - Flufirvitide-3 - Nucleozin - Small Molecule For Influenza A - ET-001 - CR-8043 - FI-6 - Pam2Cys Vaccine For more information visit http://www.researchandmarkets.com/research/wj...nfluenza_a